American biopharmaceutical company at Alameda in California, founded in 2025, which develops medicines given through the nose for emergency use. Works on a next generation intranasal naloxone for opioid overdose designed to reach blood levels close to those of an injection, and builds its delivery platform for other emergency treatments that need to act quickly.
Aucun commentaire disponible.
Laissez votre note & commentaire